SCHEMBL19282289

SCHEMBL19282289

CN(C)CCNC(=O)c1cccc(-n2cc(CSc3cc(N)nc4[nH]nnc34)c(C(F)F)n2)c1

nearest known ligand 0.78

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 9/20 0.78
▸ PARP1 P09874 2/20 0.40
▸ MAP4K4 O95819 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ FYN P06241 3/20 0.36
▸ PRKD1 Q15139 2/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ PRKD2 Q9BZL6 1/20 0.35
▸ CAMK2D Q13557 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19282243 0.87 MPO (0.60) MPOPARP1MAP4K4
SCHEMBL19282193 0.81 MPO (0.54) MPO
SCHEMBL19282233 0.78 MPO (0.48) MPO
SCHEMBL19282350 0.78 MPO (0.57) MPO
SCHEMBL19282288 0.76 MPO (0.71) MPO
SCHEMBL19282222 0.74 MPO (0.73) MPO
SCHEMBL19282215 0.71 MPO (0.71) MPO
SCHEMBL19282306 0.69 MPO (0.75) MPOPARP1
SCHEMBL19282271 0.69 MPO (0.69) MPO
SCHEMBL19282313 0.68 MPO (0.69) MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10981879-B2 Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-20 — — US claimed
EP-3191486-B1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2018-08-01 — — EP claimed
US-10981879-B2 Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-20 — — US disclosed
US-10981879-B2 Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-20 — — US disclosed
US-20190031623-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2019-01-31 — — US disclosed
US-20190031623-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2019-01-31 — — US disclosed
EP-3191486-B1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2018-08-01 — — EP disclosed
US-20170247343-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-31 — — US disclosed
US-20170247343-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-31 — — US disclosed
US-20170247343-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031623-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 MPO 2/4885PARP1 869/4885MAP4K4 1624/4885
US-20170247343-A1 THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 MPO 2/4885PARP1 869/4885MAP4K4 1624/4885
US-10981879-B2 Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase EPX, MPO, SERPINB1 MPO 2/4885PARP1 869/4885MAP4K4 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback